(Q46369839)

21 December 2017

title

Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study (English)

1 reference

21 December 2017

Mohammad Reza Safarinejad

1 reference

series ordinal

1

1 reference

21 December 2017

publication date

12 September 2008

1 reference

21 December 2017

published in

Urologic Oncology

1 reference

21 December 2017

volume

28

1 reference

21 December 2017

issue

1

1 reference

21 December 2017

page(s)

21-27

1 reference

21 December 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

About sorafenib in castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Circulating neuroendocrine markers in patients with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

The McGill Pain Questionnaire: Major properties and scoring methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Satraplatin in the treatment of hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

Epothilones and the next generation of phase III trials for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.06.003

10.1016/J.UROLONC.2008.06.003

7 January 2021

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017